ATE259378T1 - Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen - Google Patents

Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen

Info

Publication number
ATE259378T1
ATE259378T1 AT96939218T AT96939218T ATE259378T1 AT E259378 T1 ATE259378 T1 AT E259378T1 AT 96939218 T AT96939218 T AT 96939218T AT 96939218 T AT96939218 T AT 96939218T AT E259378 T1 ATE259378 T1 AT E259378T1
Authority
AT
Austria
Prior art keywords
brca2
cancer
sequencing
identification
susceptileity
Prior art date
Application number
AT96939218T
Other languages
English (en)
Inventor
Phillip Andrew Futreal
Richard Francis Wooster
Alan Ashworth
Michael Rudolf Stratton
Original Assignee
Cancer Res Campaign Tech
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE259378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9523959.6A external-priority patent/GB9523959D0/en
Priority claimed from GBGB9525555.0A external-priority patent/GB9525555D0/en
Priority claimed from GBGB9617961.9A external-priority patent/GB9617961D0/en
Application filed by Cancer Res Campaign Tech, Univ Duke filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of ATE259378T1 publication Critical patent/ATE259378T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96939218T 1995-11-23 1996-11-25 Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen ATE259378T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9523959.6A GB9523959D0 (en) 1995-11-23 1995-11-23 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of cancer
GBGB9525555.0A GB9525555D0 (en) 1995-12-14 1995-12-14 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of cancer
GBGB9617961.9A GB9617961D0 (en) 1996-08-28 1996-08-28 Materials and methods relating to the diagnosis and prophylactic and therapeuti treatment of cancer
PCT/GB1996/002904 WO1997019110A1 (en) 1995-11-23 1996-11-25 Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof

Publications (1)

Publication Number Publication Date
ATE259378T1 true ATE259378T1 (de) 2004-02-15

Family

ID=27267991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939218T ATE259378T1 (de) 1995-11-23 1996-11-25 Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen

Country Status (10)

Country Link
US (1) US6045997A (de)
EP (1) EP0858467B1 (de)
JP (1) JP2001507563A (de)
AT (1) ATE259378T1 (de)
AU (1) AU707636C (de)
CA (1) CA2238010A1 (de)
DE (1) DE69631540T2 (de)
DK (1) DK0858467T3 (de)
ES (1) ES2217328T3 (de)
WO (1) WO1997019110A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
ATE230759T1 (de) * 1995-12-18 2003-01-15 Myriad Genetics Inc Chromosom 13 verbundene brustkrebsempfindlichkeitsgen brca2
AU773601B2 (en) * 1995-12-18 2004-05-27 Endorecherche Inc. Chromosome 13-linked breast cancer susceptibility gene
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US20030129589A1 (en) 1996-11-06 2003-07-10 Hubert Koster Dna diagnostics based on mass spectrometry
US6635452B1 (en) 1996-12-10 2003-10-21 Sequenom Inc. Releasable nonvolatile mass label molecules
EP0972078B1 (de) * 1997-03-20 2005-06-01 Affymetrix, Inc. (a California Corporation) Iterative resequenzierung
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
EP2275575A3 (de) * 1997-08-15 2012-07-11 Gene Logic Inc. Menschliche BRCA2-Gen-kodierende Sequenzhaplotypen
US20140302494A9 (en) * 1997-08-15 2014-10-09 Myriad Genetics, Incorporated Method of analyzing a brca2 gene in a human subject
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US6562958B1 (en) * 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
MXPA01008605A (es) * 1999-02-24 2003-06-24 Juan Saus Proteina de enlace del antigeno goodpasture.
WO2001029269A2 (en) 1999-10-21 2001-04-26 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
AT409381B (de) * 2000-03-03 2002-07-25 Gloessl Josef Dr Xylosyltransferase-gen
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
EP1370684B1 (de) 2000-06-15 2008-05-28 Novartis Vaccines and Diagnostics, Inc. Polynukleotide zur bestimmung von kolonkrebs
WO2002004628A2 (en) * 2000-07-06 2002-01-17 Genvec, Inc. Method of identifying a binding partner of a gene product
EP1299950B1 (de) 2000-07-13 2008-05-21 CT-Concept Technologie AG Verfahren und vorrichtung zur zustandsabhängigen regelung des transienten verhaltens von leistungshalbleiterschaltern
US20030175749A1 (en) * 2001-12-08 2003-09-18 Jong-Yoon Chun Annealing control primer and its uses
AU2003253632A1 (en) * 2002-06-10 2003-12-22 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7892823B2 (en) * 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8759089B2 (en) * 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US20130058979A1 (en) * 2009-11-30 2013-03-07 Agency For Science, Technology And Research Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
PT3126528T (pt) 2014-04-04 2021-09-09 Crown Bioscience Inc Taicang Métodos para determinar a responsividade a inibidores de mek/erk
US11773449B2 (en) 2017-09-01 2023-10-03 The Hospital For Sick Children Profiling and treatment of hypermutant cancer
CN116179710B (zh) * 2023-03-14 2023-11-24 成都诺森医学检验有限公司 基于高通量测序平台的brca1/2基因突变检测的引物组、文库构建与环化方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132191T1 (de) * 1989-04-19 1996-01-15 Hoffmann La Roche Auflösbare interferon-gamma-rezeptoren sowie verfahren zu deren herstellung
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
WO1995019360A1 (en) * 1994-01-14 1995-07-20 Taisho Pahrmaceutical Co., Ltd. Thiazoline derivative

Also Published As

Publication number Publication date
CA2238010A1 (en) 1997-05-29
AU707636B2 (en) 1999-07-15
EP0858467B1 (de) 2004-02-11
JP2001507563A (ja) 2001-06-12
EP0858467A1 (de) 1998-08-19
US6045997A (en) 2000-04-04
AU7635096A (en) 1997-06-11
DE69631540D1 (de) 2004-03-18
ES2217328T3 (es) 2004-11-01
DE69631540T2 (de) 2005-01-27
WO1997019110A1 (en) 1997-05-29
DK0858467T3 (da) 2004-06-14
AU707636C (en) 2003-01-16

Similar Documents

Publication Publication Date Title
ATE259378T1 (de) Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen
EP1295944A3 (de) GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
EP1005540A4 (de) Ikk-beta proteines, nukleinsäuren und verfahren
ATE280226T1 (de) Genetische marker für brust und eierstockkrebs
ATE295889T1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
SI0917571T1 (en) Agouti-related gene
EP1126034A3 (de) Kodierende Sequenzen des menschlichen BRCA1-Gens
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
EP0845032A4 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
DE3650266D1 (de) DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von "mullerian inhibiting substance"-ähnlichen Polypeptiden.
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
EP0947583A3 (de) Expressionsaktivierende Nukleinsäurefragmente des Melanom-inhibierenden Proteins (MIA)
EP1100815A4 (de) Von protease typ ii spaltbares peptid
DE602004028381D1 (en) Er of regulator of imprinted sites) moleküls
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
DE69931759D1 (de) Methode zur erstellung von genexpressionsprofilen
CY1110911T1 (el) Ανθρωπινο γονιδιο tsc403
WO2001060985A3 (en) Compositions, methods and kits relating to uridine phosphorylase gene mutations
WO2005049818A3 (en) Genes encoding human deubiquitinating enzymes
DE60222669D1 (de) Asthma-assoziiertes gen
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0858467

Country of ref document: EP